Developing radio-immunotherapeutic drugs for cancer patients.
Camel-IDS has raised €37M across 1 funding round from 2 investors, most recently a Series A round in Nov 2018. Based in Brussels, Belgium; founded 2014; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2018-11-21 | Series A | €37M |
| Gimv,V-Bio Ventures |
| View deal → |
